Why Enlivex Ltd.’s (ENLV) Stock Is Down 7.37%
As of Friday, July 17, Enlivex Ltd.’s ENLV share price has dipped by 7.37%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.
Commentary & Analysis
Why Enlivex Ltd.’s (ENLV) Stock Is Down 7.62%
As of Thursday, July 16, Enlivex Ltd.’s ENLV share price has dipped by 7.62%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Enlivex Ltd.’s (ENLV) Stock Is Down 11.99%
As of Thursday, July 16, Enlivex Ltd.’s ENLV share price has dipped by 11.99%, which has investors questioning if this is right time to buy.Omar Beirat
Why Enlivex Ltd.’s (ENLV) Stock Is Down 5.79%
As of Wednesday, July 15, Enlivex Ltd.’s ENLV share price has dipped by 5.79%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Enlivex Ltd.’s (ENLV) Stock Is Down 9.90%
As of Tuesday, July 14, Enlivex Ltd.’s ENLV share price has dipped by 9.90%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | ENLV | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $21.9 | $288.9 | 10% |
|
| Shares Out (Mil) | 8.2 | 54.0 | 18% |
|
| Institutional Ownership | 37.8% | 93.1% | 15% |
|
| Float (Mil) | 5.3 | 41.4 | 13% |
|
| Beta | 1.52 | 0.94 | 83% |
|
| Avg Daily Volume (000s) | 291 | 480 | 51% |
|
| Price Change (52-week) |
(92.1%) | 59.9% | 3% |
|
| Growth | ENLV | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | 154.5% | (10.1%) | 100% |
|
| EPS (5yr) | 97.9% | 15.9% | 99 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (17.8%) | (15.6%) | 39% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | ($0.310) | ($1.150) | ($0.210) | |
| Month Ago EPS | na | na | na | |
| # Rev Up | 1 | 0 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.150) | ($0.750) | na | |
| Year/Year Chg | (100.2%) | (100.3%) | na | |
| Financials | ENLV | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | $1,236 | ($43) | 88% |
|
| EPS (TTM) | $405.568 | ($1.500) | 100% |
|
| Operating Cash Flow (TTM) (Mil) | ($10) | ($31) | 20% |
|
| Net Cash Flow (TTM) (Mil) | ($1) | $2 | 39% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 14% |
|
| Enterprise Value (Q1) (Mil) | $105 | $190 | 21% |
|
| Valuation | ENLV | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.01 | 2.84 | 0% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ENLV | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | 104.9% | (47.7%) | 100% |
|
| ROE | 126.2% | (55.0%) | 97% |
|
| Liabilities to Assets | 16.8% | 29.6% | 11% |
|
| F-Score | 3 | 3 | na |
|
Enlivex Ltd. did not pass any screens on 9/2/2026.
